Publications by authors named "R M M Hupperts"
Article Synopsis
- - The study examines the effectiveness of high-efficacy disease-modifying treatments (hDMTs) versus low-efficacy treatments (lDMTs) in reducing spinal cord lesions in multiple sclerosis (MS) patients, noting the limited previous data on this specific outcome.
- - Researchers analyzed data from patients with relapse-onset MS who underwent MRI scans before and after starting treatment, comparing new lesions in both cord and brain areas.
- - Results indicate that while hDMTs significantly reduced new brain lesions and MS relapses compared to lDMTs, they did not show a significant benefit in preventing new spinal cord lesions.
Multiple sclerosis immunomodulatory treatments such as cladribine, which affects both B- and T-lymphocytes, can potentially alter the humoral response to SARS-CoV-2 vaccination. This monocenter retrospective study reports on anti-SARS-CoV-2 IgG antibody response in cladribine treated MS patients and we compare the response in patients vaccinated before and after an 18-week interval after last cladribine dose. Of the 34 patients (5 patients ≤ 18 weeks and 29 patients > 18 weeks after last cladribine dose) that were included, 32 reached seropositivity (94 %).
View Article and Find Full Text PDFA disparity exists between spinal cord and brain involvement in multiple sclerosis (MS), each independently contributing to disability. Underlying differences between brain and cord are not just anatomical in nature (volume, white/grey matter organization, vascularization), but also in barrier functions (differences in function and composition of the blood-spinal cord barrier compared to blood-brain barrier) and possibly in repair mechanisms. Also, immunological phenotypes seem to influence localization of inflammatory activity.
View Article and Find Full Text PDFBackground: Multiple sclerosis (MS) negatively affects health-related quality of life (HRQoL).
Objective: To evaluate HRQoL in people with highly active relapsing MS treated with cladribine tablets (CladT; 3.5 mg/kg cumulative dose over 2 years) in CLARIFY-MS.